Compare Stocks: BRNS, GNLX, BDTX, and TLSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.88	$1.98	$1.60 ▼ $4.94	$108.01M	3.31	561,171 shs	378,260 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.66	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
GNLX Genelux	$2.48	$2.68	$2.29 ▼ $8.53	$112.20M	0.57	253,066 shs	139,608 shs
TLSA Tiziana Life Sciences	$1.01	$1.00	$0.76 ▼ $2.33	$128.53M	0.52	611,348 shs	382,695 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	-4.08%	-15.70%	+7.43%	-44.71%
BRNS Barinthus Biotherapeutics	0.00%	+0.01%	-0.83%	+12.03%	-39.34%
GNLX Genelux	0.00%	-1.98%	-6.77%	-14.48%	-40.95%
TLSA Tiziana Life Sciences	0.00%	+11.53%	0.00%	-17.89%	-50.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$1.88	$1.98	$1.60 ▼ $4.94	$108.01M	3.31	561,171 shs	378,260 shs
BRNS Barinthus Biotherapeutics	$0.74	$0.66	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
GNLX Genelux	$2.48	$2.68	$2.29 ▼ $8.53	$112.20M	0.57	253,066 shs	139,608 shs
TLSA Tiziana Life Sciences	$1.01	$1.00	$0.76 ▼ $2.33	$128.53M	0.52	611,348 shs	382,695 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	-4.08%	-15.70%	+7.43%	-44.71%
BRNS Barinthus Biotherapeutics	0.00%	+0.01%	-0.83%	+12.03%	-39.34%
GNLX Genelux	0.00%	-1.98%	-6.77%	-14.48%	-40.95%
TLSA Tiziana Life Sciences	0.00%	+11.53%	0.00%	-17.89%	-50.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	2.64	Moderate Buy	$10.25	445.21% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
GNLX Genelux	2.80	Moderate Buy	$18.00	625.81% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRNS, GNLX, BDTX, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	GNLX Genelux	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	1.54	$0.53 per share	3.57	$1.97 per share	0.95
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
GNLX Genelux	$10K	11,219.52	N/A	N/A	$0.30 per share	8.27
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	$22.37M	-$0.75	N/A	N/A	N/A	N/A	-32.10%	-25.21%	11/5/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BRNS, GNLX, BDTX, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	7.28	7.28
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
GNLX Genelux	N/A	2.39	2.39
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BRNS Barinthus Biotherapeutics	25.20%
GNLX Genelux	37.33%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	9.29%
BRNS Barinthus Biotherapeutics	8.50%
GNLX Genelux	7.50%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	21	57.45 million	52.12 million	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
GNLX Genelux	26	45.24 million	41.85 million	Not Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

BRNS, GNLX, BDTX, and TLSA Headlines

Recent News About These Companies

Tiziana Life Sciences Completes Last Patient Last Visit in Phase 2A Inform-Ms Trial of Intranasal Foralumab

September 22, 2026 | marketscreener.comM

BTIG Research Reaffirms "Buy" Rating for Tiziana Life Sciences (NASDAQ:TLSA)

September 22, 2026 | marketbeat.com

Tiziana Doses Final Patient In Phase 2a INFORM-MS For Foralumab; Topline Data In Oct '26

September 21, 2026 | rttnews.com

Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October

September 21, 2026 | finance.yahoo.com

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

September 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

September 21, 2026 | proactiveinvestors.com

Tiziana Life Sciences Ltd(NasdaqCM:TLSA) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Why is Tiziana Life Sciences stock gaining Thursday?

September 17, 2026 | msn.com

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

September 17, 2026 | rttnews.com

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

September 17, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

September 17, 2026 | markets.businessinsider.com

Tiziana Life Sciences consensus price target decreased by 11.11% to $8.16

September 15, 2026 | msn.com

Tiziana Life Sciences (TLSA) Expected to Post Quarterly Earnings on Friday

September 11, 2026 | marketbeat.com

BTIG initiates coverage of Tiziana Life Sciences (TLSA) with buy rating

September 3, 2026 | msn.com

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

September 3, 2026 | proactiveinvestors.com

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

August 24, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

August 24, 2026 | globenewswire.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

August 6, 2026 | insidertrades.com

Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

August 2, 2026 | finanznachrichten.de

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, GNLX, BDTX, and TLSA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$1.88 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.89 +0.01 (+0.37%)

As of 09/25/2026 07:55 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 09/25/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Genelux NASDAQ:GNLX

$2.48 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.57 +0.09 (+3.59%)

As of 09/25/2026 07:30 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.01 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.00 (+0.10%)

As of 09/25/2026 07:30 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, GNLX, BDTX, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, GNLX, BDTX, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, GNLX, BDTX, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, GNLX, BDTX, and TLSA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Barinthus Biotherapeutics NASDAQ:BRNS

Genelux NASDAQ:GNLX

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, GNLX, BDTX, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, GNLX, BDTX, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, GNLX, BDTX, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, GNLX, BDTX, and TLSA Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Barinthus Biotherapeutics NASDAQ:BRNS

Genelux NASDAQ:GNLX

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools